MedTrace Logo

Venous Thromboembolism Prophylaxis Post Cesarean Section

NCT01321788 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2012-02-06

No results posted yet for this study

Summary

Pregnancy is associated with an overall 5-10 fold increased risk of venous thromboembolism (VTE). VTE remains the most common cause of maternal death in the developed world. It is up to 10 times more common in pregnant women than non-pregnant women of comparable age. More than a third of pregnancy-related VTE occurs during the six weeks after delivery. When compared with vaginal delivery, cesarean delivery further increases the risk of pregnancy associated VTE by three-fold.

Conditions

Interventions

DRUG

TINZAPARIN

Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.

DRUG

PLACEBO

Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.

Sponsors & Collaborators

  • King AbdulAziz City for Science and Technology

    collaborator OTHER

  • King Saud University

    lead OTHER

Principal Investigators

  • FARJAH H ALGAHTANI, MD · King Saud University

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01321788 on ClinicalTrials.gov